These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36209121)

  • 1. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up.
    Conduit C; Koh TT; Hofman MS; Toner GC; Goad J; Lawrentschuk N; Tai KH; Lewin JH; Tran B
    Cancer Imaging; 2022 Oct; 22(1):58. PubMed ID: 36209121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we rely on PET in the follow-up of advanced seminoma patients?
    Siekiera J; Małkowski B; Jóźwicki W; Jasiński M; Wronczewski A; Pietrzak T; Chmielowska E; Petrus A; Kamecki K; Mikołajczak W; Kraśnicki K; Chłosta P; Drewa T
    Urol Int; 2012; 88(4):405-9. PubMed ID: 22507953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
    Decoene J; Winter C; Albers P
    Urol Oncol; 2015 Jan; 33(1):23.e15-23.e21. PubMed ID: 25454484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Loriot Y; Texier M; Culine S; Fléchon A; Thiery-Vuillemin A; Gravis G; Geoffrois L; Chevreau C; Gross-Goupil M; Barthelemy P; Bompas E; Mahammedi H; Laguerre B; Lacourtoisie SA; Helissey C; Ladoire S; Abraham C; Massard C; Grimaldi S; Fizazi K
    Eur Urol; 2022 Aug; 82(2):172-179. PubMed ID: 35599187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF; O'Doherty MJ; Timothy AR; Leslie MD; Harper PG; Huddart RA
    Br J Cancer; 2000 Oct; 83(7):863-9. PubMed ID: 10970686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography in the postchemotherapy management of patients with seminoma: systematic review and meta-analysis.
    Treglia G; Sadeghi R; Annunziata S; Caldarella C; Bertagna F; Giovanella L
    Biomed Res Int; 2014; 2014():852681. PubMed ID: 24963486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT impact on testicular tumours clinical management.
    Ambrosini V; Zucchini G; Nicolini S; Berselli A; Nanni C; Allegri V; Martoni A; Rubello D; Cricca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):668-73. PubMed ID: 24265073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of 18F-FDG PET/CT in Characterization of Equivocal Lesions in High-Risk Testicular Carcinoma in Restaging Setting.
    Rasheed R; Al-Kandari F; Ghanem M; Marafi F; Usmani S
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):511-515. PubMed ID: 32102532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of 18F-FDG PET/CT in the management of testicular cancers.
    Cook GJ; Sohaib A; Huddart RA; Dearnaley DP; Horwich A; Chua S
    Nucl Med Commun; 2015 Jul; 36(7):702-8. PubMed ID: 25757201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Role of Early Interim Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced Seminoma Undergoing Standard Treatment.
    Raggi D; Bandini M; Giannatempo P; Farè E; Marandino L; Colecchia M; Calareso G; Padovano B; Serafini G; Alessi A; Necchi A
    Clin Genitourin Cancer; 2021 Jun; 19(3):237-245.e2. PubMed ID: 32980271
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Petrović J; Beatović S; Šobić-Šaranović D; Odalović S; Stojiljković M; Grozdic-Milojevic I; Veljkovic M; Jovanovic D; Artiko V
    Hell J Nucl Med; 2022; 25(1):19-25. PubMed ID: 35388800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy for Post-Chemotherapy Residual Mass in Advanced Seminoma: A Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Risk-adapted Approach.
    Murthy V; Karmakar S; Carlton J; Joshi A; Krishnatry R; Prabhash K; Noronha V; Bakshi G; Prakash G; Pal M; Menon S; Agrawal A; Rangarajan V
    Clin Oncol (R Coll Radiol); 2021 Jul; 33(7):e315-e321. PubMed ID: 33608206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
    De Santis M; Bokemeyer C; Becherer A; Stoiber F; Oechsle K; Kletter K; Dohmen BM; Dittrich C; Pont J
    J Clin Oncol; 2001 Sep; 19(17):3740-4. PubMed ID: 11533096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
    Bachner M; Loriot Y; Gross-Goupil M; Zucali PA; Horwich A; Germa-Lluch JR; Kollmannsberger C; Stoiber F; Fléchon A; Oechsle K; Gillessen S; Oldenburg J; Cohn-Cedermark G; Daugaard G; Morelli F; Sella A; Harland S; Kerst M; Gampe J; Dittrich C; Fizazi K; De Santis M
    Ann Oncol; 2012 Jan; 23(1):59-64. PubMed ID: 21460378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up.
    Karapetis CS; Strickland AH; Yip D; Steer C; Harper PG
    Intern Med J; 2003; 33(9-10):427-35. PubMed ID: 14511195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
    Becherer A; De Santis M; Karanikas G; Szabó M; Bokemeyer C; Dohmen BM; Pont J; Dudczak R; Dittrich C; Kletter K
    Eur J Radiol; 2005 May; 54(2):284-8. PubMed ID: 15837411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma.
    Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B
    J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.